Live feed
·
INSIDERFilingvia Quantisnow
Indaptus Therapeutics Inc. logo

Indaptus Therapeutics (INDP) executive Waltzman received 75,000 Stock Option (Right to Buy)

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Roger J. Waltzman (Chief Medical Officer at Indaptus Therapeutics Inc., INDP) reported that they received 75,000 Stock Option (Right to Buy) on Oct 9, 2024.

Reporting person
Waltzman Roger J.
Role
Chief Medical Officer

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Oct 9, 2024Grant or award (A)Stock Option (Right to Buy)On 75,000 Common Stock1+75,000--75,000 direct

Holdings before and after

  • Stock Option (Right to Buy): 0 to 75,000 direct

Footnotes from the filing

  1. 1. The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Transaction codes in this filing

Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Waltzman report in this INDP Form 4?

Roger J. Waltzman (Chief Medical Officer at Indaptus Therapeutics Inc., INDP) reported that they received 75,000 Stock Option (Right to Buy) on Oct 9, 2024.

What does transaction code A mean on an SEC Form 4?

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Historical context for INDP

Earlier insider filings at INDP

Quantisnow market dataNASDAQ
Indaptus Therapeutics Inc. logo
INDP
Indaptus Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Get push alerts for INDP

Follow INDP and get a push notification the moment its next story breaks.

Full INDP profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INDP (Indaptus Therapeutics Inc.) and more on Quantisnow.